Inmunoterapia en cáncer de vejiga - page 20

The randomize setting: Pembrolizumab
Pembrolizumab significantly increased OS
Vs chemotherapy
Benefit was observed across all PD-L1subgroups
1...,10,11,12,13,14,15,16,17,18,19 21,22,23,24,25,26,27,28,29,30,...36
Powered by FlippingBook